公司风险 - 公司面临着与重大国际业务相关的风险，包括外汇波动风险[20] - 公司在全球市场面临激烈竞争，包括来自本地竞争对手和其他大型跨国公司的竞争[23] - 公司的业务增长依赖于成功识别、开发和推出创新的新产品[25] - 公司面临与流行病、流行病或类似广泛公共卫生关切相关的各种风险[28] - 全球经济不确定性或不利条件可能对公司业务产生负面影响，包括消费者减少消费、供应商面临财务困难等情况[47] 公司运营 - 公司依赖信息技术系统进行业务运营，包括与内部和外部各方的沟通、订单管理、产品制造、客户服务、市场营销等[41] - 公司的信息技术系统存在遭受计算机病毒、未经授权访问、网络攻击等风险，可能导致数据泄露和系统故障[42] - 公司定期升级信息技术系统或采用新技术，但如果升级或新技术出现问题，可能对业务产生不利影响，包括产品交付、发票处理等方面[43] 公司财务 - 公司2022年全球净销售额为179.67亿美元，较2021年增长3.0%[68] - 公司2022年口腔、个人护理和家居护理产品部门的净销售额为142.54亿美元，较2021年增长1.0%[68] - 公司2022年Hill's宠物营养产品的净销售额为37.13亿美元，较2021年增长12.0%[69] - 公司2022年全球毛利为102.48亿美元，较2021年下降1%[70] - 公司2022年销售、一般和管理费用为65.65亿美元，较2021年增长2%[71] 公司财务管理 - 公司使用非GAAP财务指标来评估业绩和趋势，如净销售增长和有机销售增长[95] - 公司通过发行债券和债务融资来支持业务和增长计划，2022年长期债务总额为8766百万美元[98] - 公司2022年现金及现金等价物减少57百万美元，至2022年底为775百万美元[99] - 公司2022年资本支出为696百万美元，预计2023年资本支出将占净销售的4.0%[98] - 公司2022年经营活动现金净额为2556百万美元，较2021年的3325百万美元下降[98]

Colgate-Palmolive 4Q and Full Year 2022 Earnings Presentation January 2023 Notice for Investor Presentation Please review the following fourth quarter and full year 2022 earnings release slide presentation in conjunction with our fourth quarter and full year 2022 earnings press release, prepared remarks and additional information regarding our non-GAAP financial measures. Our presentation contains non-GAAP financial measures, which differ from our reported results prepared in accordance with U.S. generally ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to________ . Commission File Number: 1-644 COLGATE-PALMOLIVE COMPANY (Exact name of registra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to________ . Commission File Number: 1-644 COLGATE-PALMOLIVE COMPANY (Exact name of registrant as ...

Colgate-Palmolive Company (NYSE:CL) Q1 2022 Earnings Conference Call April 29, 2022 8:30 AM ET Company Participants John Faucher - Chief Investor Relations Officer Noel Wallace - Chairman, President and Chief Executive Officer Stan Sutula - Chief Financial Officer Conference Call Participants Dara Mohsenian - Morgan Stanley Peter Grom - UBS Andrea Teixeira - JPMorgan Wendy Nicholson - Citi Olivia Tong - Raymond James Steve Powers - Deutsche Bank Jason English - Goldman Sachs Lauren Lieberman - Barclays Javi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to________ . Commission File Number: 1-644 COLGATE-PALMOLIVE COMPANY (Exact name of registrant a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-644 | --- | --- | --- | |---------------------------------------|---------------------|---------------------------------------------- ...